Name (Synonyms) | Correlation |
---|
There is one clinical trial.
Magnetic properties of myocardial tissue change in the presence of disease. This is detectable in the change of rate of magnetic relaxation, and measurable by T1 and T2 mapping using cardiovascular magnetic resonance (CMR). These markers provide novel quantifiable imaging measures for myocardial tissue characterisation. Despite similar principles the measurements differ considerably between different sequences, vendors and field strengths, yielding a necessity to establish robust sequence-specific normal ranges, diagnostic accuracy and prognostic relationships in apparently healthy subjects with no known heart disease. A further unknown relates to separation between healthy myocardium and the subclinical disease in several groups of patients with suspected cardiac involvement. Examples include patients with systemic inflammatory conditions, as well as patients with a recent COVID-19 infection.
Description: number of deaths
Measure: All-cause mortality Time: 1 yearDescription: number of deaths
Measure: All-cause mortality Time: 5 yearsDescription: Number of participants with events including death due to heart failure and and hospitalisation due to Heart Failure
Measure: Heart Failure Outcome Time: 1 year and 5 yearsDescription: Number of participants with death due to myocardial infarction, heart failure, arrhythmia or vascular events (pulmonary embolism, aortic dissection, stroke)
Measure: Cardiovascular Outcome Time: 1 year and 5 yearsDescription: Number of participants with documented events including sudden cardiac death, appropriate ICD discharge, sustained VT
Measure: Arrhythmia Outcome Time: 1 year and 5 years